阿斯利康在华淘金的步伐可能要踌躇一段时间了——这家被称为“最懂中国市场”的外资药企正卷入到了前所未有的危机当中。几天前,阿斯利康在收到深圳海关出具的《移送审查起诉告知书》及《鉴定意见通知书》后,在2024年财报中坦率承认:被查涉嫌偷逃进口税款90万美元,涉及英飞凡、替西木单抗两款抗癌药,最高可能面临450万美元的天价罚款。这意味着,在阿斯利康公司层面,案件已经进入检察院审查起诉阶段。若犯罪事实充分...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.